averaged GNF SymAtlas + NCI-60 cancer cell lines, human (Su, 2004; Ross, 2000)
Gene | Promoter | Pearson corr. coef. | P-value | Plot |
---|---|---|---|---|
CEBPA | hg19_v2_chr19_-_33793430_33793470 | 0.61 | 3.1e-23 | Click! |
Promoter | Log-likelihood | Transcript | Gene | Gene Info |
---|---|---|---|---|
chr12_+_69742121 Show fit | 41.01 |
ENST00000261267.2
ENST00000549690.1 ENST00000548839.1 |
lysozyme |
|
chr20_-_43883197 Show fit | 39.77 |
ENST00000338380.2
|
secretory leukocyte peptidase inhibitor |
|
chr6_-_32557610 Show fit | 32.18 |
ENST00000360004.5
|
major histocompatibility complex, class II, DR beta 1 |
|
chr9_+_130911770 Show fit | 27.71 |
ENST00000372998.1
|
lipocalin 2 |
|
chr9_+_130911723 Show fit | 26.64 |
ENST00000277480.2
ENST00000373013.2 ENST00000540948.1 |
lipocalin 2 |
|
chr17_+_1665345 Show fit | 21.00 |
ENST00000576406.1
ENST00000571149.1 |
serpin peptidase inhibitor, clade F (alpha-2 antiplasmin, pigment epithelium derived factor), member 1 |
|
chr12_-_10007448 Show fit | 20.36 |
ENST00000538152.1
|
C-type lectin domain family 2, member B |
|
chr10_-_21786179 Show fit | 19.11 |
ENST00000377113.5
|
cancer susceptibility candidate 10 |
|
chr19_-_6720686 Show fit | 17.79 |
ENST00000245907.6
|
complement component 3 |
|
chr8_-_6837602 Show fit | 17.17 |
ENST00000382692.2
|
defensin, alpha 1 |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
1.7 | 77.9 | GO:0019731 | antibacterial humoral response(GO:0019731) |
2.7 | 62.8 | GO:0006957 | complement activation, alternative pathway(GO:0006957) |
10.9 | 54.3 | GO:0015891 | iron chelate transport(GO:0015688) siderophore transport(GO:0015891) |
8.5 | 42.3 | GO:0002399 | MHC class II protein complex assembly(GO:0002399) |
8.4 | 42.2 | GO:0016998 | cell wall macromolecule catabolic process(GO:0016998) |
6.6 | 32.9 | GO:0071279 | cellular response to cobalt ion(GO:0071279) |
1.7 | 25.4 | GO:0042167 | porphyrin-containing compound catabolic process(GO:0006787) tetrapyrrole catabolic process(GO:0033015) heme catabolic process(GO:0042167) pigment catabolic process(GO:0046149) |
0.4 | 24.7 | GO:0018279 | protein N-linked glycosylation via asparagine(GO:0018279) |
2.0 | 24.0 | GO:1900747 | negative regulation of vascular endothelial growth factor signaling pathway(GO:1900747) |
0.5 | 23.8 | GO:0006953 | acute-phase response(GO:0006953) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
1.9 | 177.2 | GO:0035580 | specific granule lumen(GO:0035580) |
0.5 | 111.1 | GO:0072562 | blood microparticle(GO:0072562) |
0.9 | 84.3 | GO:0035578 | azurophil granule lumen(GO:0035578) |
0.0 | 59.3 | GO:0005887 | integral component of plasma membrane(GO:0005887) |
2.4 | 50.0 | GO:0042613 | MHC class II protein complex(GO:0042613) |
0.0 | 38.2 | GO:0016021 | integral component of membrane(GO:0016021) |
0.1 | 31.7 | GO:0016323 | basolateral plasma membrane(GO:0016323) |
2.6 | 31.0 | GO:0043203 | axon hillock(GO:0043203) |
0.2 | 28.1 | GO:0035579 | specific granule membrane(GO:0035579) |
1.8 | 25.6 | GO:0098647 | collagen type VI trimer(GO:0005589) collagen beaded filament(GO:0098647) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.9 | 95.1 | GO:0004867 | serine-type endopeptidase inhibitor activity(GO:0004867) |
0.4 | 59.7 | GO:0002020 | protease binding(GO:0002020) |
1.6 | 58.4 | GO:0042605 | peptide antigen binding(GO:0042605) |
0.2 | 56.1 | GO:0004252 | serine-type endopeptidase activity(GO:0004252) |
7.0 | 42.2 | GO:0003796 | lysozyme activity(GO:0003796) |
1.3 | 32.5 | GO:0043395 | heparan sulfate proteoglycan binding(GO:0043395) |
0.1 | 30.5 | GO:0030246 | carbohydrate binding(GO:0030246) |
0.3 | 27.7 | GO:0004866 | endopeptidase inhibitor activity(GO:0004866) |
0.4 | 27.3 | GO:0050840 | extracellular matrix binding(GO:0050840) |
6.5 | 26.1 | GO:0047006 | 17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity(GO:0047006) |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
0.4 | 95.5 | NABA ECM REGULATORS | Genes encoding enzymes and their regulators involved in the remodeling of the extracellular matrix |
0.4 | 64.4 | NABA ECM AFFILIATED | Genes encoding proteins affiliated structurally or functionally to extracellular matrix proteins |
0.4 | 54.9 | PID CMYB PATHWAY | C-MYB transcription factor network |
0.9 | 46.5 | PID INTEGRIN2 PATHWAY | Beta2 integrin cell surface interactions |
0.1 | 39.1 | NABA MATRISOME ASSOCIATED | Ensemble of genes encoding ECM-associated proteins including ECM-affilaited proteins, ECM regulators and secreted factors |
0.6 | 39.0 | PID FRA PATHWAY | Validated transcriptional targets of AP1 family members Fra1 and Fra2 |
1.5 | 35.5 | PID ERB GENOMIC PATHWAY | Validated nuclear estrogen receptor beta network |
0.7 | 33.7 | PID IL12 STAT4 PATHWAY | IL12 signaling mediated by STAT4 |
0.7 | 22.4 | ST G ALPHA S PATHWAY | G alpha s Pathway |
0.6 | 15.4 | PID ANTHRAX PATHWAY | Cellular roles of Anthrax toxin |
Log-likelihood per target | Total log-likelihood | Term | Description |
---|---|---|---|
3.1 | 64.5 | REACTOME INITIAL TRIGGERING OF COMPLEMENT | Genes involved in Initial triggering of complement |
0.7 | 59.3 | REACTOME AMYLOIDS | Genes involved in Amyloids |
2.6 | 46.4 | REACTOME DEFENSINS | Genes involved in Defensins |
2.2 | 43.2 | REACTOME REGULATION OF COMPLEMENT CASCADE | Genes involved in Regulation of Complement cascade |
1.8 | 39.8 | REACTOME TRANSLOCATION OF ZAP 70 TO IMMUNOLOGICAL SYNAPSE | Genes involved in Translocation of ZAP-70 to Immunological synapse |
0.6 | 35.1 | REACTOME CHEMOKINE RECEPTORS BIND CHEMOKINES | Genes involved in Chemokine receptors bind chemokines |
1.2 | 25.6 | REACTOME CS DS DEGRADATION | Genes involved in CS/DS degradation |
0.1 | 25.4 | REACTOME G ALPHA I SIGNALLING EVENTS | Genes involved in G alpha (i) signalling events |
0.3 | 23.8 | REACTOME PHASE1 FUNCTIONALIZATION OF COMPOUNDS | Genes involved in Phase 1 - Functionalization of compounds |
0.4 | 22.9 | REACTOME INTEGRIN ALPHAIIB BETA3 SIGNALING | Genes involved in Integrin alphaIIb beta3 signaling |